Skip to main content

Efavirenz induces alterations in lipid metabolism through AMPK activation

Background

Recent evidence suggests that the NNRTI efavirenz (EFV) contributes to changes in lipid and body fat composition that are implicated in lipoatrophy. As the liver is an important organ in lipid metabolism, we have evaluated the effects of clinically-used concentrations of EFV on mitochondrial function and cellular lipid metabolism in vitro, and the implication of AMP-activated protein kinase (AMPk), the master switch for regulation of cellular bioenergetics, in these processes.

Methods

O2 consumption in non-HIV infected Hep3B cells was measured with a Clark-type electrode. Following incubation (1 hr) with EFV (10, 25 or 50 μM), intracellular ATP was measured by fluorescence, mitochondrial membrane potential (Δψm), indicative of mitochondrial function, was analyzed by static cytometry, and AMPK was evaluated by Western blotting. In order to further study the implication of this enzyme, selected experiments were performed in cells pretreated (30 min) with the AMPK inhibitor Compound C (20 μM). The expression of the fatty acid transporter CD36 was analyzed by PCR, and the intracellular lipid content was determined by nuclear magnetic resonance (NMR) after 4 hr incubation with EFV.

Summary of results

EFV produced an immediate reduction of mitochondrial function, evident by the significant and dose-dependent inhibition of mitochondrial O2 consumption and the decrease of intracellular ATP and Δψm. This metabolic stress promoted the activation of AMPK, triggering several of its signalling pathways, as EFV induced an increment in CD36 mRNA expression and in intracellular lipid content, which could have been a result of the formation of lipid droplets. This intracellular lipid increase was not present in cells treated with Compound C, which points to a key role for AMPK in these mechanisms.

Conclusion

Given that EFV treatment is usually prolonged, these mechanisms may effect the general regulation of lipid metabolism and could cause the alterations that are characteristic of lipoatrophy.

References

  1. Blanco F: Involvement of Efavirenz in Lipodystrophy. AIDS Reviews. 2004, 6: 117-9.

    Google Scholar 

  2. Viollet B, et al: Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. Journal of Physiology. 2006, 574: 41-53. 10.1113/jphysiol.2006.108506.

    PubMed  CAS  PubMed Central  Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Blas-García, A., Ballesteros, D., Monleón, D. et al. Efavirenz induces alterations in lipid metabolism through AMPK activation. JIAS 11, P120 (2008). https://doi.org/10.1186/1758-2652-11-S1-P120

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/1758-2652-11-S1-P120

Keywords

  • Mitochondrial Function
  • Efavirenz
  • AMPK Activation
  • Hep3B Cell
  • CD36 mRNA